Engflag

Depiwhite

Quick links to important sections

Depiwhite

Depiwhite_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Depiwhite

Quick Facts

Property Description
Active Ingredients Hydrocortisone, Hydroquinone, Kojic Acid, Lactic Acid, Vitamin C, Aluminium Silicate
Form Cream (Topical dermatological preparation)
Pharmacological Class Depigmenting Agent, Combination Corticosteroid, Keratolytic Agent
General Purpose To achieve a more uniform skin tone by controlling hyperpigmentation
Origin Synthetic/Derived Multi-Component Product

What Type of Drug is Depiwhite?

Depiwhite is a specialized multi-component topical dermatological preparation used in the management of specific, severe skin discoloration and hyperpigmentation. This product is fundamentally a combination therapy, meaning it integrates multiple active ingredients to achieve a synchronized effect on pigment regulation, distinguishing it from single-agent treatments. The product is manufactured as a Cream for Topical administration, which is the necessary delivery method for localized dermatological agents.

Its pharmacological classification is multifaceted, encompassing a primary depigmenting agent, a keratolytic agent, and a preparation containing a localized anti-inflammatory agent. The formulation, often marketed by specialized dermatological manufacturers, is positioned as an intensive, prescribed solution for persistent pigmentary disorders, such as melasma, which represents a common use scenario.

Composition: The Multi-Component Active Ingredients

The therapeutic efficacy of the formulation rests on the precise combination of six active ingredients: Hydrocortisone, Hydroquinone, Kojic Acid, Lactic Acid, Ascorbic Acid (Vitamin C), and Aluminium Silicate. This complexity is specifically designed to create a comprehensive biological approach to pigmentation control.

Hydroquinone, the core component for pigment reduction, is a classified skin-lightening agent. It acts in reducing dyschromia by functioning as a powerful tyrosinase inhibitor. This component is paired with Hydrocortisone, a mild topical corticosteroid, which is included for its localized anti-inflammatory action to prevent inflammation that can otherwise stimulate pigment overproduction. The formula is further enriched by Lactic Acid, which induces a gentle keratolytic action, assisting in the accelerated shedding of existing pigmented cells.

General Purpose of the Combination Therapy

The overall purpose of the Depiwhite formulation is to achieve general improvement in skin tone uniformity by simultaneously controlling the three major factors that contribute to hyperpigmentation: new pigment synthesis, retention of existing pigment, and localized skin inflammation. This integrated combination product is functionally designed to reduce the cosmetic manifestation of dark spots by targeting these diverse pathways in a coordinated fashion, a key feature that differentiates it from simpler monotherapies.

What side effects are possible with Depiwhite?

Possible Side Effects and Safety Information

The safety profile for this multi-component topical preparation is defined by the known risks associated with its primary active ingredients, Hydroquinone and the Topical Corticosteroid (Hydrocortisone), as documented in government regulatory labeling.

Documented Adverse Reactions

The most frequently observed adverse reactions fall under Skin and Subcutaneous Tissue Disorders and are often transient, occurring primarily at the initiation of treatment. These common reactions include localized erythema (redness), a sensation of stinging or burning, and pruritus (itching). Other less common local effects documented in official labels include contact dermatitis and skin peeling.

Serious and Long-Term Safety Concerns

The preparation carries risks associated with long-term exposure, which are classified as serious in regulatory documents:

  • Exogenous Ochronosis: A serious adverse reaction associated with prolonged Hydroquinone use, resulting in a gradual, potentially irreversible blue-black or gray-blue discoloration and darkening of the skin at the application site.
  • Corticosteroid-Related Effects: Prolonged exposure to the corticosteroid component is linked to changes in skin structure, including skin atrophy (thinning), striae (stretch marks), and telangiectasia (spider veins). The label also notes the potential for HPA axis suppression due to systemic absorption, particularly with widespread use or under occlusion.

Population-Specific Safety Notes

Official labels detail safety constraints for specific groups. Pediatric patients are considered more susceptible to systemic toxicity and HPA axis suppression due to their higher skin surface area-to-weight ratio. Furthermore, the safety of the product has not been established during pregnancy or lactation, and use is only advised when clearly indicated based on regulatory standards for the active ingredients.

Absolute contraindications include a known history of hypersensitivity to any component or use on open, infected, or broken skin.

Overdose and Emergency Response

The official regulatory documentation addresses overdose scenarios for this topical preparation in two distinct categories: acute systemic exposure and complications arising from chronic, excessive use. Accidental ingestion (swallowing) of the cream is the primary documented risk for acute systemic exposure. In this event, individuals must seek emergency medical attention or call the Poison Help line immediately. Urgent medical care is also mandated if a severe, life-threatening allergic reaction occurs, characterized by symptoms such as swelling of the face, tongue, or throat, and difficulty breathing. If the affected individual is passing out or has trouble breathing, emergency services must be contacted without delay, as stated in prescribing information.

Overdose resulting from chronic, excessive application over large surface areas may lead to manifestations of systemic corticosteroid excess. The documented signs of this systemic absorption (HPA axis suppression) can include unusual tiredness, weight loss, and headaches. Pediatric patients are documented as being at a higher risk for these systemic side effects. Severe local effects, such as blistering, severe skin irritation, or Exogenous Ochronosis (blue or black skin discoloration), also require immediate cessation of use and professional consultation. Overdose management is symptomatic and supportive, as regulatory documents do not specify a known antidote.

Therapeutic Uses of Depiwhite

What Depiwhite Treats: Main Uses and Benefits

The preparation is applied across domains where additional symptomatic support is needed for acquired hyperpigmentation. The therapeutic relevance is generally aligned with supportive management for symptoms of increased physiological stress (pigmentation). In the context of depigmenting agents, such treatments are commonly used for conditions where symptoms create noticeable physiological strain related to skin discoloration.

It is relevant for managing symptoms that cluster into patterns requiring supportive management, such as the persistent dark patches of melasma (chloasma), discoloration from sun damage (lentigines), and post-inflammatory marks (PIH). The preparation is often applied in scenarios where additional management of discomfort is required for recurrent or persistent manifestations.

This preparation provides support that helps ease the overall symptom load and contributes to managing comfort during periods of heightened symptoms. It may assist with managing functional stability related to appearance by addressing chronic discoloration.

Quick Fact: Relief for Pigmentary Symptoms
Symptom Category Acquired Hyperpigmentation & Complexional Irregularities
Typical Conditions Melasma (Chloasma), Post-Inflammatory Hyperpigmentation (PIH), Sun/Age Spots
Patient Benefit Supports managing functional stability and contributes to easing discomfort related to the symptom load of discoloration.

Eligibility and Restrictions for Use

The eligibility profile for Depiwhite is strictly defined by regulatory documents based on its active ingredients, Hydroquinone and Hydrocortisone. The primary population for whom use is officially allowed is Adults.

Groups Who Must Not Use Depiwhite (Contraindications)

Use is contraindicated for individuals with a documented history of hypersensitivity or allergy to any component, including Hydroquinone, the corticosteroid, or excipients like sodium metabisulfite. The preparation is also contraindicated for pediatric patients under 12 years of age, as the safety and effectiveness profile has not been established by regulatory authorities.

Populations Requiring Conditional Use

Use is restricted and requires caution for certain groups and conditions due to the potential for systemic absorption of the corticosteroid component:

  • Reproductive Status: Caution is required for pregnant or nursing women, with labeling advising use only if the potential benefit clearly justifies the potential risk.
  • Comorbidities: Conditional use applies to patients with pre-existing endocrine or metabolic disorders, such as Diabetes or Cushing’s Syndrome, due to the risk of exacerbation.
  • Geriatric Data: No specific information is available in regulatory documents regarding the relationship of age to the effects of the active ingredients in older adults.

What should I know about interactions with other medicines?

The interaction profile for this multi-component topical preparation is determined by regulatory cautions associated with its active agents, focusing primarily on local co-administration restrictions rather than systemic drug-drug interactions.

Topical Co-administration Restrictions

Official regulatory documents mandate the restriction of co-administration with specific categories of topical products on the treatment site.

Risk of Increased Exposure: The Lactic Acid component, a keratolytic agent, has a documented potential to increase the percutaneous absorption of other medicines applied to the same area. This pharmacokinetic interaction requires that other topically applied medicines must be avoided concomitantly to prevent potentially increased systemic exposure.

Risk of Local Irritant Reinforcement: A pharmacodynamic interaction risk exists with products that can reinforce localized skin irritation. Co-administration must be avoided with substances such as medicated or abrasive soaps and cleansers, cosmetics with drying effects, and other irritant or keratolytic drugs. Similarly, the use of products with high concentrations of alcohol and astringents must be restricted to prevent additive skin toxicity, as documented in regulatory warnings for depigmenting agents.

For the topical corticosteroid component (Hydrocortisone), official prescribing information indicates that no systemic drug-drug interactions have been reported when the agent is used as directed. The overall interaction structure is defined by these mandatory timing separation and avoidance rules for local administration.

Mechanism of Action

How Depiwhite Works

The product's mechanism of action involves a coordinated, three-component strategy that influences pigment synthesis, inflammatory signaling, and cellular turnover.

Blocking Enzymatic Production of Melanin

One mechanism utilizes enzymatic inhibition within the melanogenesis pathway. Active ingredients, including Hydroquinone and Kojic Acid, function as inhibitors of the rate-limiting enzyme, tyrosinase. This molecular interaction, often through copper chelation, interferes with the chemical reactions necessary for melanin pigment synthesis within skin cells.

Modulating Inflammation that Triggers Pigment

A second mechanism involves localized modulation of inflammatory signaling. The Hydrocortisone component functions as a Glucocorticoid Receptor agonist, engaging the Arachidonic Acid cascade to influence the synthesis of certain pro-inflammatory mediators. This action alters signaling dynamics that are known to influence melanocyte activity.

Accelerating Clearance of Pigment-Laden Cells

The third action focuses on physical pigment clearance via keratolysis. Lactic Acid chemically disrupts the cohesive bonds (desmosomes) between cells in the outermost skin layer, increasing epidermal cell turnover. This process facilitates the natural shedding of keratinocytes containing accumulated melanin pigment.

Dosage and Administration Information

Official Administration Guidelines for Depigmenting Combination Cream

The usage protocol for this combination topical agent, which contains Hydroquinone and a Corticosteroid, is designated for standardized short-term courses. The administration is aligned with the designated instructions for dosage, frequency, and duration of use.

Instruction Domain Official Labeled Procedure
Route of Administration TOPICAL application to the skin only. Use is explicitly restricted from oral, ophthalmic, or intravaginal routes.
Dosing & Frequency A thin film is applied once daily, typically at least 30 minutes before bedtime. The application area includes the hyperpigmented skin and a small margin of the surrounding normal-appearing skin.
Course Duration The product is indicated for short-term treatment and is not designated for maintenance therapy. Treatment is concluded once control of the condition is achieved.
Age-Group Rule Safety and effectiveness have not been established for use in pediatric patients, specifically those below the age of 12 years.

The procedural structure dictates specific steps for proper use. Before application, the skin must be cleansed and patted dry. The cream is rubbed lightly and uniformly into the affected area, taking care to avoid contact with sensitive tissues like the eyes or mouth. A critical component of the administration protocol is the mandatory concurrent use of a broad-spectrum sunscreen (SPF 30 or greater) and protective clothing during all daytime hours. This ensures the regimen is followed according to the defined protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Depiwhite

Evidence for use in Melasma (Chloasma)

Research exploring this multi-component topical class was studied in individuals with melasma, a condition characterized by periods of heightened symptoms of dark patches on the skin. The most authoritative research was evaluated in Systematic Reviews and Meta-Analyses, which summarize the findings of multiple Randomized Controlled Trials (RCTs). These studies included adult populations across various skin tones (Fitzpatrick skin types) and focused on measuring changes in standardized severity scores for melasma, such as the MASI, and assessing patient-reported outcomes describing perceived discomfort related to the discoloration.

Evidence for use in Post-inflammatory Hyperpigmentation (PIH)

Research examined the use of this type of formula in conditions like PIH, which often occurs following an injury or inflammation and outcomes linked to inflammatory or irritative states. The evidence base for PIH includes Investigator-Blinded Studies and comparative trials. Studies monitored outcomes using clinical assessments of lesion color and size, and sometimes used devices to measure the melanin content in the affected area. However, evidence is limited because the PIH research base often relies on findings extrapolated from studies originally designed to explore melasma.

Long-Term Evidence and Follow-up

Research was studied for short-term outcomes related to systemic or functional imbalance, with many trials completing their primary assessment within periods where follow-up durations were limited to 8 to 12 weeks. While these trials provide context but not individual predictions about the initial phase, long-term effects are not fully established. Studies exploring the durability of the reported changes beyond the short-term treatment period are limited. Limited information is available for long-term outcomes, and the characterization of pigmentation relapse remains insufficient compared to the initial application phase.

Key Studies & References

  1. Postinflammatory Hyperpigmentation in Patients With Skin of Color

How should Depiwhite be stored and disposed of?

The official regulatory profile for Depiwhite Cream specifies strict conditions to maintain the stability of its multi-component formulation.

Storage Requirements

  • Temperature: Store the cream at controlled room temperature, generally defined as between 20 C and 25 C. The product must be protected from freezing and excessive heat.
  • Environmental Protection: The container must be shielded from direct sunlight and excess moisture.
  • Container and Stability: The packaging must be kept tightly closed when not in use. After first opening, users must observe the labeled Period After Opening (PAO) limit to ensure product potency.
  • Child Safety: It is a mandatory requirement to keep the cream out of the sight and reach of children at all times.

Disposal Instructions

Disposal of unused or expired cream must follow established protocols. The product should not be thrown into the household trash or flushed into wastewater unless directed by the label. The recommended method is to use a community drug take-back program or to adhere to specific local pharmaceutical waste handling regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Depiwhite found in:

A-Z Index: